Portal Innovations, a venture development platform supporting early-stage life sciences companies, today announced a ...

Recursion Pharmaceuticals (NASDAQ:RXRX) reported updated clinical data for its investigational treatment for familial ...

Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the third quarter of 2026, narrower than the Zacks ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent intraday, after Sanofi finally pulled the trigger on the development of ...

New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older show deep, durable polyp burden ...

Recursion Pharmaceuticals (RXRX) news covers its AI-native Recursion OS, clinical pipeline, partnered programs, financial ...

Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.

Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

I was thinking about a program to solve Sudoku. You fill a 9x9 grid with numbers from 1 to 9. The same number must not be repeated in any row, column, or 3x3 block. When humans solve Sudoku, they look ...

Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...

On October 27, the National Association of Attorneys General (NAAG) 2026 Consumer Protection Fall Conference held its public day with panels ...

Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...